mhra

MHRA appoints Steven Davies to lead finance and commercial operations

Steven Davies will lead MHRA financial management, major investments and its commercial plan under the 2030 Strategy. No new manufacturer obligations were announced.

Eren İŞMANMDR Auditor
Türkçe oku
Conceptual illustration connecting medical-device regulation, financial planning and laboratory investment
AI-generated conceptual illustration, not a photograph of an actual event.

What Changed

The Medicines and Healthcare products Regulatory Agency (MHRA) has appointed Steven Davies as Chief Finance and Commercial Officer to support the financial delivery of its new five-year strategy.

Davies joins from Guy’s and St. Thomas’ NHS Foundation Trust, where he is Chief Financial and Investment Officer. At the MHRA, his remit will cover financial management, major investments and the commercial plan supporting the agency’s 2030 Strategy.

Who Is Affected

The appointment directly concerns MHRA leadership and financial operations. It also has institutional relevance for medical-device and medicines developers using agency services, alongside partners across health and life sciences.

Davies began his NHS career through the national finance graduate scheme in 2000. His previous positions include Chief Financial Officer and Deputy Chief Executive at Moorfields Eye Hospital NHS Foundation Trust.

Regulatory and Technical Implications

MHRA Chief Executive Lawrence Tallon linked the appointment to the strategy’s revenue streams and capital investments in technology and laboratories. He also identified improving the funding model for innovators using MHRA services and encouraging inward investment into UK life sciences as objectives.

These statements describe institutional ambitions. The announcement does not establish revised fees, new technical requirements or changes to approval procedures.

Manufacturer Actions

The appointment does not require medical-device manufacturers to submit applications, make notifications or undertake new compliance activities. References to funding and investment objectives should not be treated as newly effective manufacturer obligations.

Confirmed Dates

The MHRA published the announcement on 19 November 2026. It did not specify Davies’s starting date.

The 2030 Strategy is identified as the agency’s strategic framework, not as a manufacturer compliance deadline. No implementation timetable for industry is announced.

Official Source

The announcement was issued by the MHRA, an executive agency of the Department of Health and Social Care responsible for regulating medicines and medical devices in the UK.

MHRA press release: https://www.gov.uk/government/news/mhra-appoints-senior-nhs-executive-as-new-chief-finance-and-commercial-officer

Source and related services

MHRA appoints senior NHS executive as new Chief Finance and Commercial Officer ↗

Source date: 19/11/2026

This news provides general information and does not replace device-specific legal or conformity assessment advice.

Related news

MHRA records closure of an IDAP UCNA entry →MHRA publishes field safety notice list for 9–13 November 2026 →MHRA sets out 2026–2027 clinical investigation fee waivers →
Contact an MDR Expert